Saturday, August 2, 2025 8/2/2025

IRON OXIDE NANOPARTICLE PROBES FOR TARGET SPECIFIC MR MOLECULAR IMAGING

Award Number: R41CA137960
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2009
PERIOD OF PERFORMANCE END DATE: 05/31/2011

Group Awards By:

View Award Description

IRON OXIDE NANOPARTICLE PROBES FOR TARGET SPECIFIC MR MOLECULAR IMAGING - DESCRIPTION (provided by applicant): This NIH SBIR project intends to develop a new generation of iron oxide nanoparticles as target specific MRI contrast agents for early detection of breast cancer. Recent advances in iron oxide synthesis in organic solvents at elevated reaction temperature allow the preparation of size tunable and monodisperse particles. These hydrophobic nanoparticles can be converted to water soluble and biolinkable nanoparticles. Our extensive research has demonstrated that these nanoparticles are very stable and can be conjugated to affinity ligands for target specific imaging. Most important, they show little liver uptake but prominent renal uptake. Such phenomenon is vastly different from all literature reported results as all of them have high reticuloendothelial system (RES) uptake in the liver and spleen and none of them has renal clearance due to the relatively large size and agglomeration in vivo. In this Phase I project, we will perform rigorous in vitro, in vivo and ex vivo characterization of various affinity ligand modified iron oxide nanoparticles for targeting integrin 1v23 that is aberrantly expressed on tumor vasculature and invasive tumor cells in breast cancer. In Phase II, focus will be shifted to improving the sensitivity, further reducing reticuloendothelial system (RES) uptake, and studying the toxicity of the proposed probes. The final deliverable of this project is a highly sensitive, clinically applicable MR imaging probe for breast cancer diagnostics. PUBLIC HEALTH RELEVANCE: Breast cancer is the second leading cause of death in the United States. In 2007, about 1,444,920 new cancer cases were expected to be diagnosed, and about 559,650 Americans were expected to die of cancer-more than 1,500 people per day. Enhancing early stage cancer diagnostics is very critical to increase the survival rate of patients. The proposed iron oxide nanoparticle probe as target specific MRI contrast enhancer will provide a platform to detect tumor in its early stage.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2010 ( Subtotal = $242,892 )
2010	2010	OCEAN NANOTECH LLC	700 RESEARCH CENTER BOULEVARD	FAYETTEVILLE	AR	72701	WASHINGTON	USA	Cancer Detection and Diagnosis Research	000	2	5/27/2010	NON-COMPETING CONTINUATION	$242,892
														Subtotal = $242,892

Issue Date FY: 2009 ( Subtotal = $239,381 )
2009	2009	OCEAN NANOTECH LLC	700 RESEARCH CENTER BOULEVARD	FAYETTEVILLE	AR	72701	WASHINGTON	USA	Cancer Detection and Diagnosis Research	000	1	5/28/2009	NEW	$239,381
														Subtotal = $239,381

Grand Total All Awards = $482,273

Top

All Categories

About

Search

Reports

Data Submission

Award Information

IRON OXIDE NANOPARTICLE PROBES FOR TARGET SPECIFIC MR MOLECULAR IMAGING

Award Number: R41CA137960

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2009

PERIOD OF PERFORMANCE END DATE: 05/31/2011

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer